Here's an Interview that just went out on $ISOLF. Overall I think it sounds like 2018 is going to be very Positive Imho.
The development of cannabis as a plant medicine has exploded in recent years, with particular focus on the cannabinoid cannabidiol (CBD). CBD has been found to help treat a myriad of issues and ailments, including pain, insomnia, anxiety, stress, and migraines, just to name a few. Isodiol (CSE: ISOL) ( OTC: ISOLF) (FSE: LB6A.F) is the global leader in the advancement of cannabinoid-derived bioactive phytoceuticals, with products available in a variety of countries around the world. The company recently announced the acquisition of the rights to become the exclusive worldwide distributor of Advanced Brain Monitoring’s (ABM) Electroencephalogram (EEG) technology.
CFN Media sat down with Isodiol Chairman of the Board Aman Parmar and Director of Communications Christopher Hussey to discuss the company’s advanced R&D and how they are disrupting the CBD market – and international health as well.
Rachelle Gordon: What is the history of Isodiol?
Christopher Hussey: Isodiol International was founded in 2009 by a gentleman named Jared Berry. I know this sounds cliché, but our goal from the beginning has been to change the world through helping people live better; you will hear that in our office every single day. We are very passionate about plants, and what plants have to offer to the medicinal and the wellness community.
And so, we create both pharmaceutical and nutraceutical products, depending on the continent. Politics and legality is different in every state and country. And so, at this time, we have nutraceuticals in multiple countries and also have pharmaceuticals in some countries and we are working towards more pharmaceuticals on more continents.
RG: Tell us about your path to going public?
Aman Parmar: Prior to going public, we did two rounds of financing in late 2016, and then we did another round in February of this year, for a total of about $3 million dollars.
Then on the actual RTO round in May, we did $4.1 million dollars, which was at 12 cents. Since then, we’ve done subsequent rounds of financing at 25 and most recently, a few weeks ago, we closed a $9 million dollar round at 74 cents.
We’ve had a good movement in the stock over the last few weeks, which we can attribute to some of the major announcements we’ve put out around our hops-derived CBD, acquisitions, and some of the technologies that we have in-licensed into our portfolio. It’s been good for our investors this year as far as a returning stock goes.
RG: Isodiol sells to both large-scale operations and direct to consumers. How you benefit from both of those groups?
AP: Isodiol has the ability to partner or work with multiple verticals of people. For instance, if you’re a distributor who is creating products, or if you’re a distributor who is selling to that end user, we have raw materials on multiple levels that we can shop to that distributor.
In addition, we have an affiliate program on all of our products, a direct-to-consumer affiliate program, and we also sell our products direct-to-consumer from the house. In addition to those three, we also white label.
RG: How did Isodiol develop their new hops-derived CBD?
CH: The industry right now believes in this statement, “Cannabinoids come from cannabis.” Now, while that statement is true, it is also not true. The correct statement is, “Cannabinoids come from cannabis as well as other plants.” The industry currently has grown based on one plant and if you’re inside the industry, you’ll know there are several challenges from the political landscape, the legal landscape and also, a supply and demand landscape, depending on where you are. So imagine a future where there are multiple plants where you can derive CBD as well as terpenes as well as caryophyllene, humulene – all of the different endocannabinoids and cannabinoids, and all the different supplemental molecules.
We know, as an educated scientific community, that essential oils have some of the same properties as cannabinoids, and have some of the same properties as basil or lavender. They share multiple properties. The same is true with the cannabaceae family of plants as well as other families of plants. We’ve partnered with the right scientists and communities and we’ve introduced the very first non-cannabis CBD.
RG: How do you think that these discoveries in R&D will affect growth?
CH: There’s no place in the world where hops are illegal. So, you woke up on Monday morning and now your product suite was available to the entire population. How would that change your business? How would that change your bottom line? How would that change your possibilities?
The reality of that story is it changes the conversation. Is hops-based CBD going to change the legality in the United States? We don’t know but we’ve started the conversation. Are we going to discover other plants that make it viable? Is this going to explode the market from the $55 billion it’s going to be here in a few years? Probably. We’ve opened up entirely new marketplaces because hops isn’t illegal anywhere. Liverwort isn’t illegal anywhere. Flax seed isn’t illegal anywhere. It’s an entirely new domain and an entirely new market.
RG: What are your projections for growth?
AP: I think when you look at our market in the US, you’ll see consistent growth month over month, between $1.3 and $1.5 million in revenue. As we approach the international market and start building up Latin American and European market, I think those numbers will start to grow quite significantly.
Heading into January 2018, our revenue is increasing from $1.5 to about $2 million a month, and as we head to the back half of 2018, our projections show that we’ll be in the $2.5 to $3 million range per month in revenue.
Our profitability is one of the most important things in the sector. We are consistently running at about 18 to 22 percent dividend on our revenue, so we are profitable. Over the last few weeks we’ve had some acquisitions around the US. All these brands will be managed in their own division, and again, our running revenues are profitable within their own operations. I see revenues ramping up in 2018 on the international front, toward the back half of the year.
RG: Tell us about the recent acquisition of Be Tru Organics?
AP: They’re based out of California, and have been in operations for about a year now. It was a great acquisition for us. Keith Gordon, the CEO, has been in sales and distribution for well over 25 years, and is a really strong addition to our management team. We’ve done a real good job at infiltrating some of the more common distribution challenges in the US, and that’s all stuff that we are implementing in the market.
Be Tru will find some national distribution and what they do is they’ve branded all of their products as hemp oil, so they’ve been able to get some mainstream distribution from just branding it a bit differently than most people in this space.
RG: Why should potential investors look at Isodiol and what exposure does the company provide?
AP: Over the last six months, we’ve really focused on developing the science IP behind the products. We’ll focus on building revenues and really getting our products out there, but what differentiates us from everybody else is the science and the actually ability for us to prove out why the compound is beneficial for the human body.
I think as we push into 2018 and we start working on some of the clinical trials, and we start seeing some of the acquisitions that have happened over in the UK, I think the market and investors will see that we are truly different in that we’re investing into developing an IP portfolio that was second to none.
We’ll start seeing a lot more celebrations with mainstream universities, colleges, and professionals in helping validate that science. Developing technologies like the non-cannabis derivative CBD has been an absolute momentous announcement for us. You’ll see a lot more of that as we head into 2018.
An overall picture of Isodiol is it’s just a family of brands. We’ve done an incredible job with building up that portfolio of products that we hit different distribution channels of those in the US, Canada, and internationally. We’ve got exciting things in the pipeline that will benefit the consumer and the shareholder, you’ll see that story really start to develop within the next year.
